An observational study in Neuromuscular Diseases, sponsored by Universitaire Ziekenhuizen KU Leuven. Recruiting at 1 site in Belgium. Open to participants aged Up to 18 Years. Per ClinicalTrials.gov, last updated 2024-07-03.
Sponsored by Universitaire Ziekenhuizen KU Leuven · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 23 studies in Neuromuscular Diseases with a site in Belgium — 7 open to participants now, 11 under way, 3 of them phase 3. Neuromuscular Diseases · Belgium.
Among the 23 studies in Neuromuscular Diseases with a site in Belgium, this one is one of 3 that started in 2014, is one of 3 observational ones, reaches primary completion later than 3 of the 10 other live ones, and was the 7th registered.
361 studies on the registry are indexed under Neuromuscular Diseases; 96 are open to participants now.
Browse Neuromuscular Diseases studies →7 of the 23 studies in Neuromuscular Diseases with a site in Belgium are open now. Recruiting first, the newest first:
Avidity Biosciences, Inc. · Sites in Belgium, Australia, Canada and 7 more countries
Ages 7–16 · Men only
Centre Hospitalier Universitaire de Liege · Sites in Belgium
Ages 18+
Cliniques universitaires Saint-Luc- Université Catholique de Louvain · Sites in Belgium
Ages 6–12 · Healthy volunteers
Université Catholique de Louvain · Sites in Belgium
Ages 12–50
Laurent Servais · Sites in Belgium
Ages 2+ · Healthy volunteers
A study can be open while its sites in Belgium have not opened yet or have stopped. Only those recruiting at a site in Belgium →
Of the 69 Neuromuscular Diseases studies recruiting now, 39 (57%) set no upper age limit and 22 (32%) stop at 75 or younger; 35 take children under 18; 16 take healthy volunteers.
This study: Up to 18 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
23 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 4 · Phase 3 8
First in 2006; this study’s year is marked. 3 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 300 is above the median of 72 across 144 observational studies indexed under Neuromuscular Diseases.
Median enrollment 77 across the 20 interventional studies, 300 across the 3 observational. Of the 12 that completed or were terminated, 4 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 23 have an industry lead sponsor. The 10 most frequent:
Universitaire Ziekenhuizen KU Leuven is the lead sponsor of 965 studies on the registry; 268 are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
Universitaire Ziekenhuizen KU Leuven has 4 studies filed under Neuromuscular Diseases — fewer than ten, so there is no comparison to draw.
2 of the studies in Neuromuscular Diseases with a site in Belgium that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06185764Vertex Pharmaceuticals IncorporatedA Phase 1/2 Study of VX-670 in Adult Participants With Myotonic Dystrophy 1 (DM1) | 2027-02-02 |
| NCT07287189Satellos Bioscience, Inc.Phase 2 Study of SAT-3247 in Pediatric Ambulatory Patients | 2027-03-31 |
Add all 2 to your calendar (.ics) → With an account.
Among the 23 studies in Neuromuscular Diseases with a site in Belgium, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This project is a retrospective and prospective investigation of neuropsychological and psychosocial development of children with a neuromuscular disease.
This project is a retrospective and prospective investigation of neuropsychological and psychosocial development of children with a neuromuscular disease. Children and adolescents in UZ Leuven will be evaluated according to a psychosocial and neuropsychological protocol including different psychological tests and patient questionaires.
children and adolescents with neuromuscular disease
Inclusion criteria
Children and adolescents with Neuromuscular disease children according to neuromuscular convention UZL
Neuropsychological profile (questionnaires, neuropsychological testing) of children with myotonic dystonia type 1
Compare the outcome of the questionnaires, IQ test and other neuropsychological test to a normal population
Time frame: one year
Started Dec 2014 (actual). Primary completion is estimated for Apr 2025, 124 months after the start.
Of 64 non-industry observational studies under Neuromuscular Diseases, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 114. This study's planned 124 months is above that.
Counting every sponsor, half of 70 studies reached it within 37 months; a quarter within 12 and three quarters within 114.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Universitaire Ziekenhuizen KU Leuven →